Trajectory of cardiac troponin T following moderate-to-severe COVID-19 and the association with cardiac abnormalities.
Biomarker
COVID-19
Cardiac function
Echocardiography
Troponin
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
13 Apr 2024
13 Apr 2024
Historique:
received:
08
08
2023
accepted:
21
03
2024
medline:
14
4
2024
pubmed:
14
4
2024
entrez:
13
4
2024
Statut:
epublish
Résumé
COVID-19 has been associated with cardiac troponin T (cTnT) elevations and changes in cardiac structure and function, but the link between cardiac dysfunction and high-sensitive cardiac troponin T (hs-cTnT) in the acute and convalescent phase is unclear. To assess whether hs-cTnT concentrations are associated with cardiac dysfunction and structural abnormalities after hospitalization for COVID-19, and to evaluate the performance of hs-cTnT to rule out cardiac pathology. Patients hospitalized with COVID-19 had hs-cTnT measured during the index hospitalization and after 3-and 12 months, when they also underwent an echocardiographic study. A subset also underwent cardiovascular magnetic resonance imaging (CMR) after 6 months. Cardiac abnormalities were defined as left ventricular hypertrophy or dysfunction, right ventricular dysfunction, or CMR late gadolinium. We included 189 patients with hs-cTnT concentrations measured during hospitalization for COVID-19, and after 3-and 12 months: Geometric mean (95%CI) 13 (11-15) ng/L, 7 (6-8) ng/L and 7 (6-8) ng/L, respectively. Cardiac abnormalities after 3 months were present in 45 (30%) and 3 (8%) of patients with hs-cTnT ≥ and < 5 ng/L at 3 months, respectively (negative predictive value 92.3% [95%CI 88.5-96.1%]). The performance was similar in patients with and without dyspnea. Hs-cTnT decreased from hospitalization to 3 months (more pronounced in intensive care unit-treated patients) and remained unchanged from 3 to 12 months, regardless of the presence of cardiac abnormalities. Higher hs-cTnT concentrations in the convalescent phase of COVID-19 are associated with the presence of cardiac pathology and low concentrations (< 5 ng/L) may support in ruling out cardiac pathology following the infection.
Sections du résumé
BACKGROUND
BACKGROUND
COVID-19 has been associated with cardiac troponin T (cTnT) elevations and changes in cardiac structure and function, but the link between cardiac dysfunction and high-sensitive cardiac troponin T (hs-cTnT) in the acute and convalescent phase is unclear.
OBJECTIVE
OBJECTIVE
To assess whether hs-cTnT concentrations are associated with cardiac dysfunction and structural abnormalities after hospitalization for COVID-19, and to evaluate the performance of hs-cTnT to rule out cardiac pathology.
METHODS
METHODS
Patients hospitalized with COVID-19 had hs-cTnT measured during the index hospitalization and after 3-and 12 months, when they also underwent an echocardiographic study. A subset also underwent cardiovascular magnetic resonance imaging (CMR) after 6 months. Cardiac abnormalities were defined as left ventricular hypertrophy or dysfunction, right ventricular dysfunction, or CMR late gadolinium.
RESULTS
RESULTS
We included 189 patients with hs-cTnT concentrations measured during hospitalization for COVID-19, and after 3-and 12 months: Geometric mean (95%CI) 13 (11-15) ng/L, 7 (6-8) ng/L and 7 (6-8) ng/L, respectively. Cardiac abnormalities after 3 months were present in 45 (30%) and 3 (8%) of patients with hs-cTnT ≥ and < 5 ng/L at 3 months, respectively (negative predictive value 92.3% [95%CI 88.5-96.1%]). The performance was similar in patients with and without dyspnea. Hs-cTnT decreased from hospitalization to 3 months (more pronounced in intensive care unit-treated patients) and remained unchanged from 3 to 12 months, regardless of the presence of cardiac abnormalities.
CONCLUSION
CONCLUSIONS
Higher hs-cTnT concentrations in the convalescent phase of COVID-19 are associated with the presence of cardiac pathology and low concentrations (< 5 ng/L) may support in ruling out cardiac pathology following the infection.
Identifiants
pubmed: 38614990
doi: 10.1186/s12872-024-03854-7
pii: 10.1186/s12872-024-03854-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
206Informations de copyright
© 2024. The Author(s).
Références
Omland T, De Lemos JA, Sabatine MS, Christophi CA, Rice MM, Jablonski KA, et al. A sensitive Cardiac troponin T assay in stable coronary artery disease. N Engl J Med. 2009;361(26):2538–47. https://doi.org/10.1056/nejmoa0805299 .
doi: 10.1056/nejmoa0805299
pubmed: 19940289
pmcid: 2997684
De Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, et al. Association of Troponin T Detected with a highly sensitive assay and Cardiac structure and mortality risk in the General Population. JAMA. 2010;304(22):2503. https://doi.org/10.1001/jama.2010.1768 .
doi: 10.1001/jama.2010.1768
pubmed: 21139111
pmcid: 5621378
Myhre PL, Claggett B, Ballantyne CM, Selvin E, Røsjø H, Omland T, et al. Association between circulating troponin concentrations, left ventricular systolic and diastolic functions, and Incident Heart failure in older adults. JAMA Cardiol. 2019;4(10):997. https://doi.org/10.1001/jamacardio.2019.3113 .
doi: 10.1001/jamacardio.2019.3113
pubmed: 31483438
pmcid: 6727783
Seliger SL, Hong SN, Christenson RH, Kronmal R, Daniels LB, Lima JAC, et al. High-sensitive Cardiac troponin T as an early biochemical signature for clinical and subclinical heart failure. Circulation. 2017;135(16):1494–505. https://doi.org/10.1161/circulationaha.116.025505 .
doi: 10.1161/circulationaha.116.025505
pubmed: 28159799
pmcid: 5401621
Sandoval Y, Januzzi JJL, Jaffe AS. Cardiac Troponin for Assessment of Myocardial Injury in COVID-19: JACC Review topic of the Week. J Am Coll Cardiol. 2020;76(10):1244–58. https://doi.org/10.1016/j.jacc.2020.06.068 .
doi: 10.1016/j.jacc.2020.06.068
pubmed: 32652195
pmcid: 7833921
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708–20. https://doi.org/10.1056/NEJMoa2002032 .
doi: 10.1056/NEJMoa2002032
pubmed: 32109013
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. https://doi.org/10.1016/s0140-6736(20)30566-3 .
doi: 10.1016/s0140-6736(20)30566-3
pubmed: 32171076
pmcid: 7270627
Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of Cardiac Injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802–10. https://doi.org/10.1001/jamacardio.2020.0950 .
doi: 10.1001/jamacardio.2020.0950
pubmed: 32211816
pmcid: 7097841
Omland T, Prebensen C, Røysland R, Søvik S, Sørensen V, Røsjø H, et al. Established Cardiovascular biomarkers provide limited prognostic information in unselected patients hospitalized with COVID-19. Circulation. 2020;142(19):1878–80. https://doi.org/10.1161/circulationaha.120.050089 .
doi: 10.1161/circulationaha.120.050089
pubmed: 32910681
pmcid: 7643784
Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, et al. Outcomes of Cardiovascular Magnetic Resonance Imaging in patients recently recovered from Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5(11):1265–73. https://doi.org/10.1001/jamacardio.2020.3557 .
doi: 10.1001/jamacardio.2020.3557
pubmed: 32730619
pmcid: 7385689
Kotecha T, Knight DS, Razvi Y, Kumar K, Vimalesvaran K, Thornton G, et al. Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance. Eur Heart J. 2021;42(19):1866–78. https://doi.org/10.1093/eurheartj/ehab075 .
doi: 10.1093/eurheartj/ehab075
pubmed: 33596594
pmcid: 7928984
Lassen MCH, Skaarup KG, Lind JN, Alhakak AS, Sengeløv M, Nielsen AB, et al. Recovery of cardiac function following COVID -19 ‐ ECHOVID ‐19: a prospective longitudinal cohort study. Eur J Heart Fail. 2021. https://doi.org/10.1002/ejhf.2347 .
doi: 10.1002/ejhf.2347
pubmed: 34514713
Hendrickson BS, Stephens RE, Chang JV, Amburn JM, Pierotti LL, Johnson JL, et al. Cardiovascular evaluation after COVID-19 in 137 Collegiate athletes: results of an algorithm-guided screening. Circulation. 2021;143(19):1926–8. https://doi.org/10.1161/CIRCULATIONAHA.121.053982 .
doi: 10.1161/CIRCULATIONAHA.121.053982
pubmed: 33970675
Clark DE, Dendy JM, Li DL, Crum K, Dixon D, George-Durrett K, et al. Cardiovascular magnetic resonance evaluation of soldiers after recovery from symptomatic SARS-CoV-2 infection: a case–control study of cardiovascular post-acute sequelae of SARS-CoV-2 infection (CV PASC). J Cardiovasc Magn Reson. 2021;23(1). https://doi.org/10.1186/s12968-021-00798-1 .
Joy G, Artico J, Kurdi H, Seraphim A, Lau C, Thornton GD, et al. Prospective case-control study of Cardiovascular abnormalities 6 months following mild COVID-19 in Healthcare Workers. JACC Cardiovasc Imaging. 2021;14(11):2155–66. https://doi.org/10.1016/j.jcmg.2021.04.011 .
doi: 10.1016/j.jcmg.2021.04.011
pubmed: 33975819
pmcid: 8105493
Myhre PL, Omland T, Sarvari SI, Ukkonen H, Rademakers F, Engvall JE, et al. Cardiac troponin T concentrations, reversible myocardial ischemia, and indices of left ventricular remodeling in patients with suspected stable angina Pectoris: a DOPPLER-CIP substudy. Clin Chem. 2018;64(9):1370–9. https://doi.org/10.1373/clinchem.2018.288894 .
doi: 10.1373/clinchem.2018.288894
pubmed: 29959147
Ingul CB, Grimsmo J, Mecinaj A, Trebinjac D, Berger Nossen M, Andrup S, et al. Cardiac dysfunction and Arrhythmias 3 months after hospitalization for COVID-19. J Am Heart Assoc. 2022;11(3):e023473. https://doi.org/10.1161/JAHA.121.023473 .
doi: 10.1161/JAHA.121.023473
pubmed: 35048715
pmcid: 9238505
Øvrebotten T, Myhre P, Grimsmo J, Mecinaj A, Trebinjac D, Nossen MB, et al. Changes in cardiac structure and function from 3 to 12 months after hospitalization for COVID-19. Clin Cardiol. 2022. https://doi.org/10.1002/clc.23891 .
doi: 10.1002/clc.23891
pubmed: 35920837
pmcid: 9538691
Lerum TV, Aaløkken TM, Brønstad E, Aarli B, Ikdahl E, Lund KMA, et al. Dyspnoea, lung function and CT findings 3 months after hospital admission for COVID-19. Eur Respir J. 2021;57(4):2003448. https://doi.org/10.1183/13993003.03448-2020 .
doi: 10.1183/13993003.03448-2020
pubmed: 33303540
pmcid: 7736755
Myhre PL, Heck SL, Skranes JB, Prebensen C, Jonassen CM, Berge T, et al. Cardiac pathology 6 months after hospitalization for COVID-19 and association with the acute disease severity. Am Heart J. 2021;242:61–70. https://doi.org/10.1016/j.ahj.2021.08.001 .
doi: 10.1016/j.ahj.2021.08.001
pubmed: 34400140
pmcid: 8363180
Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults. An update from the American Society of Echocardiography and the European Association of, Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2016;17(4):412. https://doi.org/10.1093/ehjci/jew041 .
doi: 10.1093/ehjci/jew041
Dalen H, Thorstensen A, Vatten LJ, Aase SA, Stoylen A. Reference values and distribution of conventional echocardiographic doppler measures and longitudinal tissue doppler velocities in a Population Free from Cardiovascular Disease. Circ Cardiovasc Imaging. 2010;3(5):614–22. https://doi.org/10.1161/circimaging.109.926022 .
doi: 10.1161/circimaging.109.926022
pubmed: 20581050
Administration UFD, SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE. 510(k). In: Administration UFD, editor: US Food & Drug Administration 2017.
Collet J-P, Thiele H, Barbato E, Bauersachs J, Dendale P, Edvardsen T, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–367. https://doi.org/10.1093/eurheartj/ehaa575 .
doi: 10.1093/eurheartj/ehaa575
pubmed: 32860058
Williams N. The MRC breathlessness scale. Occup Med (Lond). 2017;67(6):496–7. https://doi.org/10.1093/occmed/kqx086 .
doi: 10.1093/occmed/kqx086
pubmed: 28898975
Catena C. Echocardiographic comparison of COVID-19 patients with or without prior biochemical evidence of Cardiac Injury after Recovery. 2021.
van den Heuvel FMA, Vos JL, Koop Y, van Dijk APJ, Duijnhouwer AL, de Mast Q, et al. Cardiac function in relation to myocardial injury in hospitalised patients with COVID-19. Neth Heart J. 2020;28(7–8):410–7. https://doi.org/10.1007/s12471-020-01458-2 .
doi: 10.1007/s12471-020-01458-2
pubmed: 32643071
pmcid: 7341471
Giustino G, Croft LB, Stefanini GG, Bragato R, Silbiger JJ, Vicenzi M, et al. Characterization of Myocardial Injury in patients with COVID-19. J Am Coll Cardiol. 2020;76(18):2043–55. https://doi.org/10.1016/j.jacc.2020.08.069 .
doi: 10.1016/j.jacc.2020.08.069
pubmed: 33121710
pmcid: 7588179
McCarthy CP, Raber I, Chapman AR, Sandoval Y, Apple FS, Mills NL, et al. Myocardial Injury in the era of high-sensitivity Cardiac Troponin assays. JAMA Cardiol. 2019;4(10):1034. https://doi.org/10.1001/jamacardio.2019.2724 .
doi: 10.1001/jamacardio.2019.2724
pubmed: 31389986
Lala A, Johnson KW, Januzzi JL, Russak AJ, Paranjpe I, Richter F, et al. Prevalence and impact of Myocardial Injury in patients hospitalized with COVID-19 infection. J Am Coll Cardiol. 2020;76(5):533–46. https://doi.org/10.1016/j.jacc.2020.06.007 .
doi: 10.1016/j.jacc.2020.06.007
pubmed: 32517963
pmcid: 7279721
Metkus TS, Sokoll LJ, Barth AS, Czarny MJ, Hays AG, Lowenstein CJ, et al. Myocardial Injury in severe COVID-19 compared with Non-COVID-19 Acute Respiratory Distress Syndrome. Circulation. 2021;143(6):553–65. https://doi.org/10.1161/CIRCULATIONAHA.120.050543 .
doi: 10.1161/CIRCULATIONAHA.120.050543
pubmed: 33186055